肝癌移植术后复发相关标志物的研究进展

Molecular Markers and Recurrence of Hepatocellular Carcinoma after Liver Transplantation

肝移植是治疗肝细胞肝癌(Hepatocellular carcinoma, HCC)的重要方法,但移植后的HCC复发影响了治疗效果,尽管有严格的纳入标准,但移植术后仍有较高的复发率。随着分子生物学的发展,HCC移植术后复发相关的分子标志物被不断提出并进行分析研究。在这篇综述中,我们重点关注肿瘤标志物和炎症标志物与HCC移植术后的相关性。HCC相关的肿瘤标志物主要有甲胎蛋白(Alpha-fetoprotein, AFP)、脱-γ-羧基凝血酶原(Des-gamma-carboxyprothrombin, DCP)等,相关的炎症标志物主要有C反应蛋白(C-reactive protein, CRP)、中性粒细胞淋巴细胞比值(Neutrophil lymphocyte ratio, NLR)、血小板淋巴细胞比值(Platelet lymphocyte ratio, PLR)等。但这些标志物都存在一定的缺陷,希望能通过更多的多中心的前瞻性研究,找着更好的分子标志物组合,从而更好地预测移植后复发,以希望获得更好的移植效果。

Liver transplantation is a potentially curative treatment for hepatocellular carcinoma(HCC).But,the recurrence of HCC after transplantation has seriously affected the treatment effect.Despite stringent selection criteria,recurrence occurs in a high proportion of patients transplanted for HCC.With the development of molecular biology,there are more and more molecular markers related to the recurrence after liver transplantation.In this review,we focus on the tumor markers and inflammatory markers.Tumor markers mainly include Alpha-fetoprotein(AFP),Des-gamma-carboxyprothrombin(DCP),etc.Inflammatory markers include C-reactive protein(CRP),Neutrophil lymphocyte ratio(NLR)and Platelet lymphocyte ratio(PLR),etc.However,taking into account the limitations of these markers,multicenter prospective studies are essential to find a better combination of molecular markers,which means better prediction of recurrence and better transplant treatment effect.